TMRW Life Sciences Raises $28M Series D Financing
Summary
TMRW Life Sciences, a NYC-based creator of the only FDA-cleared automated specimen management and storage platform for frozen human sperm, eggs and embryos, raised $28M in Series D funding. Led by CEO Louis Villalba, TMRW Life Sciences is a fertility technology company digitizing the IVF lab starting with automated platforms for the safe management and storage of frozen sperm, eggs and embryos. Frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. Its technology platforms set a new standard of care, reducing potential points of failure by 94% compared to manual systems. The company now has more than 60 leading fertility clinic partners serving more than 39,000 patients with more than 260,000 frozen specimens under management.